MedPath

FYUZHN FARMA, OOO

🇷🇺Russia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene

Phase 1
Conditions
Chronic Myeloid Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
First Posted Date
2016-08-31
Last Posted Date
2020-02-17
Lead Sponsor
Fusion Pharma LLC
Target Recruit Count
65
Registration Number
NCT02885766
Locations
🇷🇺

Federal Haematological Scientific Center, Moscow, Russian Federation

🇷🇺

Moscow City Centre of Hematology based on City Hospital named by S.Botkin, Moscow, Russian Federation

🇷🇺

Federal Almazov North-West Medical Research Centre, St. Petersburg, Russian Federation

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.